Short answer: acne care is the one skincare category where the regulatory route, not the formula, decides the project. In the United States an acne-treatment claim makes the product a drug; in the EU the same formula can be placed as a cosmetic provided the claim stops short of a medicinal function. Decide the route first, then build the formula around it.
Blemish control looks like just another sub-category of skincare, and it behaves like one on the production line: same emulsions, same low-pH liquids, same filling equipment. What makes it different is the surroundings. In the United States, "treats acne" is a drug function, which pulls the product under a monograph or a new drug application; the same formula, sold in the EU with a claim about the appearance of blemishes, is a cosmetic under Regulation 1223/2009. Two markets, one base, two entirely different compliance lives.
That split has consequences all the way down the chain — which actives can be used, at what levels, what the label may say, and what the batch documentation has to demonstrate. This guide covers the actives that carry an acne brief, the four manufacturing systems involved, the process points that decide whether batches match, and the traps that cost a relaunch.
Why acne care is a different kind of brief
Two distinctions organise the whole category, and getting them wrong is the most expensive mistake in it.
- Drug function versus cosmetic function. Where a claim asserts that the product treats, cures, clears or prevents a disease or a physiological condition, the product is regulated as a drug. Where the claim is limited to the appearance of the skin — visible blemishes, oiliness, the look of pores — it can be placed as a cosmetic in the EU and many other markets. The formula can be nearly identical; the claim determines the route.
- Monograph actives versus cosmetic actives. In the United States, certain actives are recognised for acne within the over-the-counter monograph framework, with defined concentration ranges and labelling. Actives outside that framework making the same claim follow a drug route — which is why a 2% salicylic acid product can sell as an OTC drug in the US and the same base as a cosmetic in Europe.
The practical instruction is to settle the claim before the formula. A brand that designs a strong "clears breakouts" position and then wants a cosmetic route has to reopen the brief, the artwork and the country strategy.
The actives that carry an acne formula
The table below maps the actives commonly used in blemish-focused formulas to their typical use levels and to the regulatory note that decides how far you can go with each one. Levels are the ranges that appear in published formulation practice.
| Active | Typical level | Function in the formula | Regulatory note that shapes the brief |
|---|---|---|---|
| Salicylic acid | 0.5–2% | Keratolytic, oil-soluble, works in the pore | Recognised within the US OTC monograph for acne at 0.5–2%; a cosmetic active in the EU when the claim stays on appearance |
| Azelaic acid | Around 10% | Multi-functional, works on uneven tone as well as blemishes | Used cosmetically at 10% in the EU; higher strengths sit on a drug route in the US. Poorly soluble, so suspension or solubilisation decides the texture |
| Niacinamide | 2–5% | Sebum regulation, barrier support, tone | Cosmetic in both markets; the friendly co-active when the primary active limits the claim |
| Zinc salts (for example zinc PCA) | Around 1% | Sebum control, light astringency | Cosmetic; often used to make an oil-control claim without a drug function |
| Succinic acid | 1–4% | Newer keratolytic route, positioned for sensitive skin | Cosmetic in both markets; pH-sensitive, so the vehicle has to protect the acid form |
| Tea tree oil or terpinen-4-ol | 0.5–1% | Botanical antibacterial positioning | Cosmetic in both markets. Watch allergen labelling and oxidation, which drives colour drift |
| Sulfur | 3–8% | Recognised in the US OTC monograph framework for acne | Compatibility with fragrance and packaging liners is poor; odour and staining have to be engineered out |
| Benzoyl peroxide and adapalene | — | Drug actives | Not cosmetic ingredients. A cosmetic-only supply chain cannot place them, and a brief that assumes otherwise is misrouted from the start |
Two notes carry into any brief: the strongest perceived efficacy comes from the drug route, and almost every successful product is multi-active — one keratolytic at the top of its range, one sebum-regulating co-active, and one soothing agent for the irritation the first two cause.
Four formats, four manufacturing systems
Acne lines are usually built as a system rather than a single hero SKU, and each format runs on its own manufacturing system with its own order floor and lead time:
- Cleansers and body washes. Surfactant systems, with the highest order floor of the skincare formats — from 2,000 pieces per SKU — because they run on a different line from emulsions. A documented example is our acne body wash base.
- Leave-on liquids, toners and serums. Low-viscosity liquids, usually a solubilised acid system at an acidic pH, from 1,000 pieces per SKU. Our salicylic acid serum base is built on this system.
- Spot treatments. Higher active load, small pack, often a local gel or lotion, from 1,000 pieces per SKU; see the spot treatment base.
- Emulsions and moisturisers. Creams and gel-creams carrying the soothing half of the system, from 1,000 pieces per SKU.
The order floor follows the manufacturing system, not the category — which is why a two-SKU acne launch can carry two different minimums in the same basket. Model that before finalising the range with the MOQ and order volume calculator.
Process points that decide batch consistency
Acne formats are unforgiving in five specific places. Each one has a batch-failure mode behind it.
- Dissolution, not just dispersion. Salicylic acid has limited water solubility, so it is carried in a glycol, an alcohol or a solubiliser system. Get the ratio wrong and the product clouds at low temperature or crystallises on the shelf. Fix it with a documented solubilisation window verified at the low end of the storage range.
- The pH window is the efficacy window. The free-acid fraction that does the work depends on pH, and the effective window is narrow and acidic. If pH drifts upward over shelf life — which it can, because packaging and excipients interact — efficacy falls away while the label still claims the same concentration. Batch records need a pH at release and at end of shelf life, not one figure.
- Preservative performance at low pH. Acidic vehicles change which preservative systems work; a formula inherited from a neutral cream and dropped into an acidic toner will usually fail the preservative efficacy test.
- Metal contact and colour drift. Trace metals accelerate discolouration in acid systems and in botanical routes such as tea tree, and stainless-steel contact parts are not automatically inert.
- Suspension stability. An insoluble active dispersed in a gel or lotion settles unless the yield stress is right: too little and the active deposits in the tube shoulder, too much and the product will not dispense cleanly. Measure it — viscosity at two temperatures plus a settling check on the filled pack.
Colour and texture are held against a retained Golden Sample, verified under daylight and warm light, because blemish products are often sold in sets where two units sit side by side in one photograph.
The development traps that cost a relaunch
- Claim drift in the copy. The formula is built as a cosmetic and the copy asserts a drug function, which makes the product a misbranded drug and turns the remedy into a relabelling exercise.
- Stacking too many keratolytics. A cleanser, toner and treatment all containing an acid looks like a strong system and behaves like an irritation event. Barrier support is not decoration here — see our barrier repair manufacturing guide.
- Ignoring the purge conversation. Users often see a temporary worsening in the first weeks; if the pack, insert and customer-service script do not set that expectation, the product is returned for a reason the formula cannot fix.
- Building the toning claim onto the wrong active. Uneven tone accompanies blemishes, and the actives that address it are not always those that address the breakout. A range that mixes the two without a plan ends up with two half-claims; the combination logic is in our brightening actives guide.
- Assuming one market's claim schedule fits the other. A claim approved in one market can be a drug function in the next, so country-specific claim discipline belongs in the brief rather than at artwork stage.
How to brief an acne project
A brief that survives contact with a regulatory reviewer contains five things:
- The claim you intend to make, in the exact words, per market.
- The actives and their target levels, with the vehicle and pH window the brief assumes.
- The format list and the order quantity per format, so the manufacturing systems and their floors can be matched to volumes.
- The irritation-management story — what in the formula soothes, and how that is substantiated.
- The documentation you need at shipment: analysis against specification, stability summary and microbiological report, plus destination-ready filing documentation.
Get those five down and the rest is engineering. Skip one and the project re-opens at the least convenient moment — usually at artwork approval.
FAQ
Q: Is an acne product a cosmetic or a drug? A: It depends on the claim, not the formula. Where the claim asserts that the product treats, clears or prevents acne as a condition, it is regulated as a drug; where the claim is limited to the appearance of the skin, it can be placed as a cosmetic in the EU and many other markets. The same base can travel both routes.
Q: What levels of salicylic acid are used in blemish formulas? A: Published practice for leave-on blemish products sits at 0.5–2%, the same range recognised within the US over-the-counter monograph framework for acne. The level that works in your product depends on the vehicle, pH window and destination claim rules.
Q: Why do the order floors differ between an acne cleanser and an acne serum? A: Because the floor follows the manufacturing system, not the category. Surfactant systems such as cleansers and body washes start from 2,000 pieces per SKU; emulsion and low-viscosity liquid systems start from 1,000. A range mixing formats carries mixed minimums in one basket.
Q: Why does an acidic blemish formula fail preservative testing more often than a cream? A: Because pH changes which preservative systems perform. A package validated in a neutral emulsion can fail when moved into an acidic toner or gel, and the failure is usually found during efficacy testing rather than at release. It has to be re-validated for the actual vehicle and pH.